Source: Eye Future ；Editor:Liu XinyiReprint Requirements: Can be reprinted 24 hours after the first publication, source must be credited.
2023Year11Month29Zilia Inc., a company dedicated to non-invasively detecting ocular biomarkersZiliaAnnounced that itsZilia Ocular™ FCRetinal Camera ApprovedFDA 510（K）。
# Zilia Ocular™ FC Retinal CameraZilia Ocular™ FC Retinal Camera is aFundus Camera(Fundus Camera). A fundus camera refers to an instrument that examines and diagnoses the fundus using a non-contact intraocular photography method (i.e., without going through the eyeball). This camera employs modern electronic principles, controlled by a computer, to convert the optotype signals forming images on the human retina into electrical signals. These signals are then amplified and processed, allowing the optotypes to form images on the retina, thereby completing the eye examination.This camera usesAdvanced Optical TechnologyTo obtain ocular data, andUsing AI to analyze and interpret this data, providing more comprehensive information. Zilia Ocular™ throughUtilizing the direct connection between the eyes, vascular system, and brain, a broader range of physiological information can be obtained, including early signs of eye diseases and the overall health status of the body.In addition, Zilia Ocular™ can continuously measure the blood oxygen saturation in the targeted retinal area, opening new doors for researching metabolic responses and pathophysiology of the eye and brain. Specifically, the features of this camera are as follows:Multifunctional:Zilia Ocular™ will provide two types of information —Information on eye structures obtained through imagingAndMetabolic information obtained by detecting the blood oxygen saturation of ocular tissues.Non-invasive:Zilia Ocular™ usesLow-Intensity White Light, which can collect ocular data in a fast and comfortable way.Continuous Monitoring:Zilia Ocular™ is able toPerform real-time measurements during the duration, This continuity enables the product to observe the real-time response of the eye to various stimuli, rather than just measurements at specific time points, which is highly valuable for studying changes and adaptive responses of the eye under different conditions.Automation:Zilia Ocular™ hasAutomatic Positioning and Focusing Function, which can improve the comfort of patients during the testing process.The general operation process of this camera is as follows: ① The light emitted by the device passes through the eye and reflects onto the fundus; ② The device analyzes the returning light signals to provide a series of images and high-quality spectra; ③ The machine processes the information in real time and displays it on the relevant display device, allowing the operator to obtain quantified biomarker data.Zilia is a Canadian company, founded in 2017, with the aim of developingNon-invasive Technologies and Platforms for Measuring Ocular Biomarkers，The initial focus of the research was on blood oxygen saturation in the eye.The company's vision is to establish a paradigm for the detection and prevention of eye diseases, enabling people to detect and treat them early. The company also hopes to use its technology to impact a range of disciplines such as neurology, cardiology, oncology, and critical care, assisting in drug development.The founders of the company are Dr. Patrick Sauvageau (a trained optometrist and vision scientist) and Dominic Sauvageau (Ph.D. in Engineering).
▲Patrick Sauvageau (Right) & Dominic Sauvageau (Left)The company has currently known to have received three funds, with the following specific information:On May 4, 2023, received an undisclosed amount of funding from CQIB (a life sciences incubator company).On August 11, 2021, Zilia Inc. raised $4 million in a seed funding round led by Anges Quebec, with participation from Investissement Quebec.On June 25, 2019, received an undisclosed amount of non-equity assistance from Creative Destruction Lab.
